Melanotan 1 Nasal Spray

MT1 nasal spray is a synthetic 13-amino acid α-MSH analog studied as a selective MC1R agonist. It may activate the cAMP-mediated melanogenesis cascade in melanocyte cell models. Findings come from preclinical models only and remain limited. It is supplied strictly for laboratory research — not for human or veterinary use.

What is MT1 nasal spray?

MT1 nasal spray — also known as Melanotan 1 or afamelanotide — is a synthetic 13-amino acid analog of alpha-melanocyte-stimulating hormone (α-MSH), formulated for laboratory and preclinical research use. Behemoth Labz supplies this compound as a research-grade nasal spray for investigators studying MC1R receptor pharmacology, melanogenesis signaling, and pigmentation biology in controlled experimental settings.

As a selective melanocortin 1 receptor (MC1R) agonist, afamelanotide is applied in experimental settings to probe the cAMP-mediated melanogenesis cascade — the intracellular signaling pathway through which MC1R governs pigmentation biology in melanocyte cell models. The nasal delivery format provides a controlled, reproducible route of administration for in vitro and preclinical study protocols. Observed associations are not consistent across all models, and data remain limited.

Disclaimer: MT1 (Melanotan 1 / afamelanotide) is a research compound not approved by the U.S. Food and Drug Administration (FDA) for human or veterinary use. It is not intended to diagnose, treat, cure, or prevent any disease. This product is strictly for laboratory research purposes only.

Physicochemical Profile

How Does MT1 (Melanotan 1) Interact with MC1R?

MT1 (afamelanotide) is studied as a potent, selective agonist of the melanocortin 1 receptor (MC1R) in experimental models. MC1R is a G-protein-coupled receptor expressed primarily on melanocytes. Upon MT1 binding, the receptor is thought to activate adenylyl cyclase, converting ATP to cyclic adenosine monophosphate (cAMP). Elevated intracellular cAMP then drives the following cascade, as characterised in Mel-Ab and B16 melanocyte cell line preparations:

MC1R → cAMP → PKA → CREB phosphorylation → MITF upregulation → tyrosinase expression

Picture it this way: MT1 docks at the extracellular binding pocket of MC1R, triggering a conformational shift that couples the receptor to the Gαs protein. Adenylyl cyclase is activated at the intracellular face. cAMP floods the cytoplasm. PKA is released from its regulatory subunits, migrates to the nucleus, and phosphorylates CREB at Ser-133. Phosphorylated CREB binds the CRE motif in the MITF promoter. MITF expression rises. Tyrosinase — the rate-limiting enzyme in melanin biosynthesis — is transcribed.

This signaling cascade is the established mechanistic framework within which MT1 is investigated across independent research groups, though findings vary across experimental systems.

How Does MT1 Differ from Native α-MSH?

MT1 is engineered for greater metabolic stability than native α-MSH. Native α-MSH has an estimated half-life of approximately 10 minutes in vivo, owing to rapid proteolytic degradation at susceptible amino acid residues. MT1’s two structural modifications address this limitation directly:

• Nle4 substitution — replaces the oxidation-prone methionine at position 4 with norleucine, a structurally similar but metabolically stable residue.
• D-Phe7 substitution — introduces a D-amino acid configuration at position 7, sterically hindering peptidase access and extending biological activity in preclinical models.

Together, these modifications produce a compound reported to be approximately 26-fold more potent than native α-MSH in adenylyl cyclase assay systems, positioning MT1 as a common reference compound in MC1R pharmacology and melanogenesis pathway research.

MT1 vs MT2 — Research Comparison

MT1 and MT2 differ in structure and receptor selectivity. MT1 is a linear, MC1R-selective peptide; MT2 is a cyclic, non-selective melanocortin agonist.

MT1’s structural linearity and MC1R selectivity distinguish it from MT2, whose cyclic architecture and multi-receptor engagement make it a different research tool for melanocortin system studies.

What Are the Research Applications of MT1 Nasal Spray?

MT1 is applied as a selective MC1R agonist across several intersecting preclinical research domains. Its documented receptor binding affinity and metabolic stability give it a defined position as a reference tool.

MC1R Receptor Pharmacology

Within melanocortin receptor pharmacology, MT1 is applied as a reference agonist in studies characterising MC1R binding kinetics, receptor occupancy, and G-protein coupling efficiency. Its reported 26-fold potency advantage over native α-MSH and defined structural modifications (Nle4, D-Phe7) allow researchers to establish dose-response relationships in receptor activation assays. Mel-Ab and B16 melanocyte cell lines serve as primary experimental models.

cAMP-Mediated Melanogenesis Pathway Studies

The MC1R → cAMP → PKA → CREB → MITF → tyrosinase cascade is the primary research framework for MT1 investigations. Researchers apply MT1 in laboratory studies examining how MC1R gene polymorphisms may affect cAMP signaling efficiency and downstream eumelanin/pheomelanin ratio shifts, though findings vary across experimental models and data remain limited.

Eumelanin/Pheomelanin Ratio Research

Research suggests that defective MC1R signaling — resulting from receptor gene mutations — may shift pigmentation toward pro-oxidant pheomelanin at the expense of eumelanin in preclinical models. MT1 is used in laboratory settings to investigate how selective MC1R agonism may modulate this ratio, with attention to the downstream oxidative stress implications of pheomelanin predominance. Observed associations are not consistent across all models (Böhm, 2026).

Antimelanogenesis Pathway Comparison Studies

MT1 serves as the positive control reference compound in studies screening inhibitors of the melanogenesis pathway. Research examining compounds such as Theasinensin A uses established MC1R → tyrosinase cascade methodology in B16 cell models (Lim et al., 2021) — the same framework within which MT1 activity is characterised. MT1 provides the receptor-activation benchmark against which pathway inhibition is measured.

Nasal Delivery Pharmacokinetics Research

The nasal spray format is itself a research variable in peptide delivery studies. Intranasal administration bypasses first-pass hepatic metabolism and offers a controlled route for preclinical bioavailability investigations, making the formulation relevant to peptide mucosal delivery and pharmacokinetic research protocols.

What Are the Risks and Limitations of MT1 Research?

This section is mandatory reading before working with MT1 in any laboratory setting.

• Handling Precautions: MT1 nasal spray should be handled by trained laboratory personnel only, in a controlled research environment. Full PPE is mandatory — nitrile gloves, safety eyewear, and a lab coat. All spray handling must be conducted in a ventilated workspace. Avoid all inhalation or nasal contact with spray output during experimental use, and avoid any skin contact with spray output.
• Exposure Risks: MT1 is a synthetic MC1R agonist research peptide that is thought to activate the cAMP-mediated melanogenesis cascade in preclinical models. The nasal spray delivery format may increase systemic absorption risk relative to lyophilized powder due to faster potential uptake via the intranasal route. No human safety data exists for this research-grade formulation.
• Storage: Store MT1 nasal spray at −20°C in sealed vials, protected from light and moisture. Once opened, store at 4°C and use within 7 days. Do not allow the spray mechanism to contact non-sterile surfaces. Avoid repeated freeze-thaw cycling.
• Toxicity and Data Limitations: No chronic toxicity data exist for this research-grade formulation of MT1. All mechanistic and pharmacological findings are derived from short-duration preclinical models only. Data remains limited and is not consistent across all experimental systems. MT1 is listed on the WADA 2026 Prohibited List under Section S2 (Peptide Hormones, Growth Factors, Related Substances and Mimetics), prohibited both in- and out-of-competition.

What to Look for in a Supplier When Buying Research-Grade MT1 Nasal Spray?

Check that every batch is independently third-party tested for purity and identity, and that a batch-specific Certificate of Analysis — not a generic representative document — is available for each lot. You can try trusted sites like BehemothLabz, where all compounds are sold strictly for preclinical and in vitro research use.

• In stock — MT1 nasal spray available for dispatch to qualified research facilities
• Independent third-party HPLC testing — every production lot, before release
• USA-made to research-grade standards — consistent 100 mcg per actuation
• Fast shipping for researchers — orders processed and dispatched promptly upon verification
• Research-use-only labeling compliant with applicable standards

Note: All BehemothLabz products are strictly for LABORATORY AND RESEARCH PURPOSES ONLY. They are not to be used for any human or veterinary purposes.

Frequently Asked Questions

What is MT1 nasal spray used for in research?

MT1 nasal spray (afamelanotide) is applied in laboratory settings to study MC1R receptor pharmacology, cAMP-mediated melanogenesis signaling, and pigmentation pathway biology in preclinical models. It is not approved for human or veterinary use.

How is MT1 nasal spray different from MT2?

MT1 is a linear 13-amino acid peptide acting as a selective MC1R agonist, studied primarily for melanogenesis pathway research. MT2 is a shorter, cyclic 7-amino acid peptide engaging MC1R, MC3R, MC4R, and MC5R non-selectively. MT1 holds FDA approval as Scenesse for an unrelated indication; MT2 has no approved indication.

What is the purity of BehemothLabz MT1 nasal spray?

≥99% purity, verified by independent third-party HPLC analysis on every production lot, with a batch-specific Certificate of Analysis available per lot.

What is the WADA status of MT1?

MT1 (Melanotan 1 / afamelanotide) is listed on the WADA 2026 Prohibited List under Section S2. It is prohibited both in- and out-of-competition for all athletes subject to WADA or equivalent anti-doping jurisdiction.

Is MT1 nasal spray FDA approved?

Afamelanotide is FDA-approved as Scenesse for erythropoietic protoporphyria via a subcutaneous implant. The research-grade nasal spray formulation supplied by BehemothLabz is not the approved clinical preparation and has not been evaluated for safety under uncontrolled conditions.

Where can researchers buy MT1 nasal spray?

MT-I is available at BehemothLabz for qualified laboratory use. Every batch is independently third-party HPLC tested at ≥99% purity with a batch-specific Certificate of Analysis.

References

1. Böhm, M. (2026). Hormones and skin pigmentation: fundamentals and clinical relevance. Dermatologie, 77(1), 9–17. https://pubmed.ncbi.nlm.nih.gov/41489668/
2. Lim, H. Y., Kim, E., Park, S. H., Hwang, K. H., Kim, D., Jung, Y. J., Kopalli, S. R., Hong, Y. D., Sung, G. H., & Cho, J. Y. (2021). Antimelanogenesis effects of Theasinensin A. International Journal of Molecular Sciences, 22(14), 7453. https://pubmed.ncbi.nlm.nih.gov/34299073/

⚠️ ATTENTION — LABORATORY AND RESEARCH PURPOSES ONLY: MT1 nasal spray (afamelanotide) is strictly for controlled laboratory and investigational research use. Not for human or veterinary use. Not approved by the FDA for any consumer or clinical application outside its approved Scenesse indication. All research must comply with IRB guidelines and IACUC directives under the Animal Welfare Act (AWA). By purchasing, you agree to BehemothLabz Terms and Conditions.